US20140031547A1 - CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES - Google Patents

CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES Download PDF

Info

Publication number: US20140031547A1
Authority: US; United States
Prior art keywords: alkyl; aryl; heteroaryl; conh; groups
Prior art date: 2010-12-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US13/993,288

Other languages

English (en)

Inventor

Joseph M. Sheridan

Jonathan R. Heal

William D.O. Hamilton

Ian Pike

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Proteome Sciences PLC

Original Assignee

Electrophoretics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-14

Filing date

2011-12-14

Publication date

2014-01-30

2010-12-14 Priority claimed from GBGB1021161.3A external-priority patent/GB201021161D0/en

2011-06-01 Priority claimed from GBGB1109162.6A external-priority patent/GB201109162D0/en

2011-12-14 Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd

2013-09-19 Assigned to ELECTROPHORETICS LIMITED reassignment ELECTROPHORETICS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAMILTON, WILLIAM D.O., HEAL, JONATHAN R, PIKE, IAN, SHERIDAN, JOSEPH M

2014-01-30 Publication of US20140031547A1 publication Critical patent/US20140031547A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Definitions

the invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1 ⁇ ) inhibitors and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
CK1 ⁇ casein kinase 1 delta
Alzheimer's disease also known as senile dementia of the Alzheimer type (SDAT), primary degenerative dementia of the Alzheimer's type (PDDAT), or Alzheimer's
SDAT senile dementia of the Alzheimer type
PDAT primary degenerative dementia of the Alzheimer's type
Alzheimer's is the most common form of dementia. Most often, Alzheimer's disease is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer's is predicted to affect 1 in 85 people globally by 2050.
Alzheimer's disease is a neurodegenerative disease characterised by the presence of senile plaques and neurofibrillary tangles in the brain.
the degree of dementia at death correlates better with neurofibrillary tangle numbers than with senile plaques counts.
the presence of neurofibrillary tangles in neurons results in the death of those neurons, implying that prevention of tangle formation is an important therapeutic goal.
the principal protein that forms the neurofibrillary tangle is the microtubule-associated protein, tau, which assembles into filaments that have the appearance of twisting about each other in pairs and are referred to as paired helical filaments (PHF).
PHF paired helical filaments
Intraneuronal deposits of tau in the form of typical neurofibrillary tangles of AD or other morphologically distinct tau aggregates in a number of other neurodegenerative diseases is the basis for grouping these conditions as tauopathies.
the main examples of the tauopathies are frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
the intracellular tau deposits (usually neuronal but can also be glial) are all filamentous and mostly in a hyperphosphorylated state compared to the level of phosphorylation of tau from control human brain. In the case of AD, this hyperphosphorylated tau is often referred to as PHF-tau because it is derived from the PHF.
Tau is a phosphoprotein, the function of phosphorylation remaining to be unequivocally established.
increased phosphorylation of tau on multiple serine and threonine residues reduces the ability of tau to promote microtubule assembly and to stabilise assembled microtubules, effects that have been demonstrated both in vitro and in cells.
Many studies have shown that PHF-tau from AD brain is more heavily phosphorylated on serine and threonine than tau from control brain.
casein kinase 1 Mammalian casein kinase-1 exists as multiple isoforms CK1 ⁇ , CK1 ⁇ , CK1y1, CK1y2, CK1y3, CK1 ⁇ and CK1 ⁇ .
the role of CK1 ⁇ as a potential tau kinase is of particular interest since it has been reported that CK1 ⁇ protein is increased more than 30-fold in the hippocampus of Alzheimer brain compared to equivalent controls (Ghoshal, N. et al (1999) Am. J.
Pathol 155, 1163-1172 while its mRNA content is increased 24-fold (Yasojima, K. et al (2000) Brain Res 865, 116-120) and CK1 has also been shown to be tightly associated with PHF (Kuret, J. et al (1997) J. Neurochem 69, 2506-2515).
CK1 ⁇ has also been reported to phosphorylate tau at two epitopes detecting using phospho-specific monoclonal antibodies to tau, and exogenous expression of CK1 ⁇ in non-neuronal cells reduces binding of tau to microtubules (Li, G. et al (2004) J. Biol. Chem. 279, 15938-15945).
CK1 activity is stimulated by amyloid beta-peptide (A ⁇ ), a component of the senile neuritic plaques that, together with tangles, characterise Alzheimer brain (Chauhan, A. et al (1993) Brain Res. 629, 47-52). Additional evidence for possible involvement of CK1 in Alzheimer's disease comes from the reported influence of CK1 in the regulation of A ⁇ production in neurons (Flajolet, M. et al (2007) PNAS USA 104, 4159-4164). Further work has confirmed that at least 6 newly identified phosphorylation sites in PHF-tau (all on serine or threonine residues) can be generated by CK1 ⁇ .
a ⁇ amyloid beta-peptide
CK1 ⁇ inhibitors which may be of potential therapeutic benefit in the treatment of neurodegenerative diseases, such as tauopathies including Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
tauopathies including Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, and multisystem atrophy (MSA).
a pharmaceutical composition comprising a compound of formula (IA) or a pharmaceutically acceptable salt or solvate thereof:
Het A represents a 4 or 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
X and Y independently represent a bond, —C(R 7a )(R 8a )-, (CH 2 ) 2 , —O—, —S—, —CH 2 —O—, —(CH 2 ) 2 —O—, NR 6a , —N(R 6a )—C(R 7a )(R 8a )-, —N(R 6a )-(CH 2 ) 2 -, —N(R 6a )-(CH 2 ) 3 -, —CH 2 —N(R 6a )-(CH 2 ) 2 -, —N(R 6a )—CO—, —CH
R 5a represents hydrogen, C 1-6 alkyl or cyano
R 6a represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, C 3-8 cycloalkyl, —CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R 7a )(R 8a )-heteroaryl, wherein said aryl groups of R 6a may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7a and R 8a independently represent hydrogen or C 1-6 alkyl
R 1a and R 2a independently represent aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1a and R 2a may be substituted by one or more (e.g. 1, 2 or 3) R 4a groups;
R 4a represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, —CONH 2 , —CH 2 —CONH 2 , —NH—C 1-6 alkyl, —NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl
n an integer from 0 to 3;
the compound is other than compound number 38, 138, 212, 243, 378, 415, 441, 480, 577, 579, 580, 587-589, 593, 598, 600, 629, 636, 678, 684, 747, 760, 802, 861, 871, 873, 879, 883, 897-899, 904-905, 907, 909, 915, 917-919, 922-923, 925, 929-930, 938-939, 961.
the compound of formula (IA) is selected from any of compounds: 1, 4-17, 19-25, 36-37, 39-40, 42, 44-45, 52, 61, 71-76, 80-83, 86-91, 93-97, 102-107, 110-112, 114, 117-122, 139-143, 149-151, 153, 158-160, 163-170, 174-177, 185-197, 200, 202-203, 208-209, 211, 213-221, 223-224, 226, 228-229, 232, 234, 237-240, 256, 261-264, 267-268, 270, 272, 275-283, 296, 304, 313, 319, 321-323, 326-328, 332, 334-335, 342-345, 350, 356, 361-365, 367-369, 372, 377, 379, 383, 393, 398, 403, 406, 412-413, 416-423, 431-432, 434, 436, 438-
the compound of formula (IA) is selected from any of compounds:
the compound of formula (IA) is selected from any of compounds:
the compound of formula (IA) is selected from any of compounds:
the compound of formula (IA) is selected from any of compounds:
the compound of formula (IA) is selected from any of compounds:
the compound of formula (IA) is selected from any of compounds:
composition comprising a compound of formula (IB) or a pharmaceutically acceptable salt or solvate thereof:
Het B represents a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
R 5b represents hydrogen, C 1-6 alkyl or cyano
R 6b represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, COOH, —COOC 1-6 alkyl, C 3-8 cycloalkyl, —CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —O—CO—heteroaryl, —CO-heteroaryl or —C(R 7b )(R 8b )-heteroaryl, wherein said aryl groups of R 6b may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7b and R 8b independently represent hydrogen or C 1-6 alkyl
R 1b represents aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1b may be substituted by one or more (e.g. 1, 2 or 3) R 4b groups;
R 4b represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, -COOH, —CO—C 1-6 alkyl, —COO—C 1-6 alkyl, -CONH 2 , —CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl
n an integer from 0 to 3;
the compound is other than compound number 54, 373, 458, 496, 585, 590, 594, 596-597, 601-602, 649, 703, 778, 877, 891, 910, 912, 926 and 962-963.
the compound of formula (IB) is selected from any of compounds 2-3, 26-28, 30-33, 35, 47-48, 51, 57-60, 63-64, 78, 84, 113, 123, 127-129, 145, 155-157, 171-173, 204, 206-207, 210, 225, 227, 233, 235-236, 241-242, 244, 249, 269, 285, 288, 303, 307-312, 314-316, 320, 324-325, 333, 336, 351, 357-360, 374-375, 384-391, 396, 399-402, 404-405, 407-411, 414, 424-425, 427-428, 437, 448, 456-457, 482, 484-485, 489-491, 495, 497-498, 505, 507, 516, 519, 524, 526, 553, 559-560, 568, 570, 575, 609, 615-616
the compound of formula (IB) is selected from any of compounds:
the compound of formula (IB) is selected from any of compounds:
the compound of formula (IB) is selected from any of compounds:
a pharmaceutical composition comprising a compound of formula (IC) or a pharmaceutically acceptable salt or solvate thereof:
Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
X c and Y c independently represent a bond, —C(R 7c )(R 8c )-, (CH 2 ) 2 , —O—, —S—, -CH 2 -O-, (CH 2 ) 2 —O—, NR 6c , —N(R 6c )—C(R 7c )(R 8c )-, —N(R 6c )—(CH 2 ) 2 -, —N(R 6c )—(CH 2 ) 3 -, —CH 2 —N(R 6c —(CH 2 ) 2 - , —N(R 6c )—CO—, -CH
R 5c represents hydrogen, C 1-6 alkyl or cyano
R 6c represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, C 3-8 cycloalkyl, —CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R 7c )(R 8c )-heteroaryl, wherein said aryl groups of R 6c may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7c and R 8c independently represent hydrogen or C 1-6 alkyl
R 1c and R 2c independently represent aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1c and R 2c may be substituted by one or more (e.g.
R 4c groups R o o represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, —COOH, —CO—C 1-6 alkyl, -COO—C 1 - 6 alkyl, -CONH 2 , -CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, -NH—COO 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—
p represents an integer from 0 to 3;
the compound is other than compound number 161, 648, 658, 680, 726, 824, 867, 880, 892, 896, 901, 903, 906, 928 and 944.
Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to one further ring to form a bicyclic ring system.
Het C represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system.
Het C represents a 6 membered heterocyclic ring system containing 1 or 2 nitrogen atoms, wherein said ring system is optionally fused to a phenyl ring to form a bicyclic ring system.
Het C represents pyridinyl, pyrimidinyl or quinazolinyl.
Het C represents quinazolinyl.
X c and Y c independently represent a bond or NR 6c . In a further embodiment, X c and Y c independently represent a bond or NH. In a yet further embodiment, one of X c and Y c represents a bond and the other represents a bond or NH. In a yet further embodiment, one of X c and Y c represents a bond and the other represents NH.
R 1c and R 2c independently represent aryl, bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1c and R 2c may be substituted by one or more (e.g. 1, 2 or 3) R 4c groups.
R 1c and R 2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g.
R 1c and R 2c may be substituted by one or more (e.g. 1, 2 or 3) R 4c groups.
R 1c and R 2c independently represent aryl (e.g. phenyl), bicyclic heterocyclyl (e.g. benzodioxinyl), monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) or bicyclic heteroaryl ring system (e.g. benzoxazolyl), wherein R 1c and R 2c may be substituted by one or more (e.g. 1) R 4c groups selected from hydroxyl, C 1-6 alkoxy (e.g. methoxy) or CONH 2 .
R 1c and R 2c independently represent aryl (e.g. phenyl) or monocyclic heteroaryl (e.g. pyridinyl, pyrazolyl or thiophenyl) wherein R 1c and R 2c may be substituted by one or more (e.g. 1) R 4c groups selected from hydroxyl, C 1-6 alkoxy (e.g. methoxy) or CON H 2 .
R 1c and R 2c independently represent unsubstituted aryl (e.g. phenyl) or unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
one of R 1c and R 2c represents unsubstituted aryl (e.g. phenyl) and the other represents unsubstituted monocyclic heteroaryl (e.g. pyridinyl or pyrazolyl).
aryl e.g. phenyl
monocyclic heteroaryl e.g. pyridinyl or pyrazolyl
p represents an integer from 0 to 2. In one embodiment, p represents 0. In an alternative embodiment, p represents 1. In an alternative embodiment, p represents 2.
R 3c represents a monocyclic heteroaryl ring system (e.g. pyridinyl).
R 3c O and cyano.
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
the compound of formula (IC) is selected from any of compounds:
a pharmaceutical composition comprising a compound of formula (ID) or a pharmaceutically acceptable salt or solvate thereof:
Het D represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
R 5d represents hydrogen, C 1-6 alkyl or cyano
R 6d represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, C 3-8 cycloalkyl, -CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R 7d )(R 8d )- heteroaryl, wherein said aryl groups of R 6d may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7d and R 8d independently represent hydrogen or C 1-6 alkyl
R 1d represents aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1d may be substituted by one or more (e.g. 1, 2 or 3) R 4d groups;
R 4d represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, -COOH, —CO—C 1-6 alkyl, -COO—C 1-6 alkyl, -CONH 2 , -CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, -NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, -CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl
q represents an integer from 0 to 3;
the compound is other than compound number 273, 286, 467, 533, 544, 571, 591, 662, 783, 795, 806, 884, 887, 895, 902, 908, 921, 932, 934, 942, 959-960 and 1001.
the compound of formula (ID) is selected from any of compounds:
the compound of formula (ID) is selected from any of compounds:
the compound of formula (ID) is selected from any of compounds:
the compound of formula (ID) is selected from any of compounds:
the compound of formula (ID) is selected from any of compounds:
a pharmaceutical composition comprising a compound of formula (IE) or a pharmaceutically acceptable salt or solvate thereof:
Het E represents a 6 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
R 5e represents hydrogen, C 1-8 alkyl or cyano
R 6e represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, cyano, C 3 - 8 cycloalkyl, - CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-8 alkylene-aryl, —C 1-8 alkylene-heteroaryl, -NH—CO- aryl, —CO-aryl, —CO-heteroaryl or —C(R 7e )(R 8e )-heteroaryl, wherein said aryl groups of Rhe may be optionally substituted by one or more halogen or C 1-8 alkoxy groups;
R 7e and R 8e independently represent hydrogen or C 1-8 alkyl
R 1e represents aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1d may be substituted by one or more (e.g. 1, 2 or 3) R 4e groups;
R 4e represents halogen, C 1-8 alkyl, C 1-8 alkenyl, C 1-8 alkynyl, C 3-8 cycloalkyl, haloC 1-8 alkyl, hydroxyl, C 1-8 alkoxy, —O—C 1-8 alkenyl, haloC 1-8 alkoxy, -COOH, —CO—C 1-8 alkyl, -COO—C 1-6 alkyl, -CONH 2 , —SO 2 NH 2 , -CH 2 —CONH 2 , -NH—C 1-8 alkyl, -NH—C 2-8 alkenyl, -NH—CO—C 1 - 6 alkyl, —CO—NH—C 1-8 alkyl, -NH-NH 2 , —O—CH 2 —CO—NH—C 1-6 alkyl, -CH 2 —CH 2 —CO—NH—C 1-8 alkyl, —S—C 1-6 alkyl, —SO—
r represents an integer from 0 to 3;
the compound of formula (IE) is selected from any of compounds:
the compound of formula (IE) is selected from any of compounds:
the compound of formula (IE) is selected from any of compounds:
the compound of formula (IE) is selected from any of compounds:
a pharmaceutical composition comprising a compound of formula (IF) or a pharmaceutically acceptable salt or solvate thereof:
Het F represents a heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S, wherein said ring system is fused to one or more (e.g. 1-3) further rings to form a polycyclic ring system comprising up to 4 rings;
R 1f represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, -COOH, —CO—C 1-6 alkyl, -COO—C 1-6 alkyl, -CONH 2 , -CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, -NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, -CH 2 —CH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl
s represents an integer from 1 to 3;
the compound of formula (IF) is selected from any of compounds:
the compound of formula (IF) is selected from any of compounds:
the compound of formula (IF) is Compound 205 as described herein or a pharmaceutically acceptable salt or solvate thereof.
the compound of this embodiment was tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 50%.
a pharmaceutical composition comprising a compound of formula (IG) or a pharmaceutically acceptable salt or solvate thereof:
R 5g represents hydrogen, C 1-6 alkyl or cyano
R 6g represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, C 3-8 cycloalkyl, -CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R 7g )(R 8g )- heteroaryl, wherein said aryl groups of R 6g may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7g and R 8g independently represent hydrogen or C 1-6 alkyl
R 1g represents aryl, C 3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein R 1g may be substituted by one or more (e.g. 1, 2 or 3) R 4g groups;
R 4g represents halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O—C 1-6 alkenyl, haloC 1-6 alkoxy, -COOH, —CO—C 1-6 alkyl, -COO—C 1-6 alkyl, -CONH 2 , -CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, -NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—CH 2 —CO—NH—C 1-6 alkyl, -CH 2 —OH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C 1-6 alkyl
t represents an integer from 0 to 3;
the compound of formula (IG) is selected from any of compounds:
the compound of formula (IG) is selected from any of compounds:
the compound of formula (IG) is compound 825 as described herein or a pharmaceutically acceptable salt or solvate thereof.
the compound of formula (IG) is selected from any of compounds: 825, 881-882, 935, 956, 968, 972 and 996 as described herein or a pharmaceutically acceptable salt or solvate thereof.
the compounds of this embodiment were tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 5%.
the compound of formula (IG) is Compound 972 as described herein or a pharmaceutically acceptable salt or solvate thereof.
the compound of this embodiment was tested in the CK1 ⁇ inhibition assay as described herein and exhibited inhibition of greater than 50%.
a pharmaceutical composition comprising a compound of formula (IH) or a pharmaceutically acceptable salt or solvate thereof:
Het H1 and Het H2 independently represent a 5 membered heterocyclic ring system containing 1 to 3 heteroatoms selected from O, N or S;
R 5h represents hydrogen, C 1-6 alkyl or cyano
R 6h represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, C 3-8 cycloalkyl, -CH 2 —C 3-8 cycloalkyl, aryl, heteroaryl, —C 1-6 alkylene-aryl, —CO-aryl, —CO-heteroaryl or —C(R 7h )(R 8h )- heteroaryl, wherein said aryl groups of R 6h may be optionally substituted by one or more halogen or C 1-6 alkoxy groups;
R 7h and R 8h independently represent hydrogen or C 1-6 alkyl
R 1h and R 2h independently represent halogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 3-8 cycloalkyl, haloC 1-6 alkyl, hydroxyl, C 1-6 alkoxy, —O-C 1-6 alkenyl, haloC 1-6 alkoxy, -COOH, —CO—C 1-6 alkyl, -COO—C 1-6 alkyl, -CONH 2 , -CH 2 —CONH 2 , -NH—C 1-6 alkyl, -NH—C 2-6 alkenyl, —NH—CO—C 1-6 alkyl, —CO—NH—C 1-6 alkyl, —O—OH 2 —CO—NH—C 1-6 alkyl, -CH 2 —OH 2 —CO—NH—C 1-6 alkyl, —S—C 1-6 alkyl, —SO—C 1-6 alkyl, —SO 2 —C
u and v independently represent an integer from 0 to 3;
the compound of formula (IH) is selected from any of compounds: 395, 433, 689 and 786 as described herein or a pharmaceutically acceptable salt or solvate thereof.
salts are intended to indicate salts which are not harmful to the patient.
Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts.
Acid addition salts include salts of inorganic acids as well as organic acids.
suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
metal salts include lithium, sodium, potassium, magnesium salts and the like.
ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzyl
the compounds of formulae (IA)-(IH) can be in racemic forms, as well as in the form of pure enantiomers or non racemic (scalemic) mixture of enantiomers, including when the compounds of formulae (IA)-(IH) have more than one stereogenic centre.
the compounds of formulae (IA)-(IH) have unsaturated carbon carbon double bonds, both the cis (Z) and trans (E) isomers and their mixtures belong to the invention.
halogen means a fluorine, chlorine, bromine or iodine atom.
C 1-6 alkyl means any linear, branched hydrocarbon groups having 1 to 6 carbon atoms, or cyclic hydrocarbon groups having 3 to 6 carbon atoms.
Representative examples of such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, n-pentyl, isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
References to “haloC 1-6 alkyl” mean a C 1-6 alkyl group substituted by one or more halogen atoms as herein defined.
C 1-6 alkylene means a saturated divalent hydrocarbon chain having the specified number of member atoms.
C 1-6 alkylene refers to a bond or an alkylene group having from 1 to 6 member atoms.
Alkylene groups may be straight or branched. Representative branched alkylene groups have one or two branches.
Alkylene includes methylene, ethylene, propylene (n-propylene and isopropylene) and butylene (n-butylene, isobutylene, and t-butylene).
C 2-6 alkenyl means any linear, branched hydrocarbon groups of 2 to 6 carbon atoms, or cyclic hydrocarbon group having 3 to 6 carbon atoms having at least one double bond.
alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
C 2-6 alkynyl means any linear, or branched hydrocarbon groups of 2 to 6 carbon atoms, having at least one triple bond.
Representative examples of such alkynyl groups include ethynyl, propargyl and butynyl.
C 1-6 alkoxy means an —O—C 1-6 alkyl group wherein C 1-6 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like.
C 3-8 cycloalkyl means a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
aryl means a C 6-12 monocyclic or bicyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, indyl or naphthyl and the like.
heteroatom means a nitrogen, sulphur, or oxygen atom.
heterocyclyl means a saturated or unsaturated non-aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heterocyclyl groups containing more than one heteroatom may contain different heteroatoms. Heterocyclyl groups may be optionally substituted with one or more substituents as defined herein. Heterocyclyl groups are monocyclic ring systems or fused bicyclic or polycyclic ring systems or bicyclic structures known as heterocyclic “spiro” ring systems. In certain embodiments, heterocyclyl is saturated. In other embodiments, heterocyclyl is unsaturated and non-aromatic.
Non-limiting examples of monocyclic heterocyclyl ring systems include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3- oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, and azetidinyl.
heteroaryl means an aromatic ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be optionally substituted with one or more substituents as defined herein. Heteroaryl groups are monocyclic ring systems or are fused bicyclic or polycyclic ring systems. Monocyclic heteroaryl rings have 5 or 6 member atoms. Bicyclic heteroaryl rings have from 7 to 11 member atoms.
Bicyclic heteroaryl rings include those rings wherein phenyl and a monocyclic heterocyclyl ring are attached forming a fused bicyclic ring system, and those rings wherein a monocyclic heteroaryl ring and a monocyclic cycloalkyl, cycloalkenyl, heterocyclyl, or heteroaryl ring are attached forming a fused bicyclic ring system.
heteroaryl includes pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furanyl, furazanyl, thienyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, cinnolinyl, benzimidazolyl, benopyranyl, benzoxazolyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzothienyl, furopyridinyl, and
heterocyclic ring system mean either a heterocyclyl ring system or a heteroaryl ring system as hereinbefore defined.
Representative compounds of the invention include compounds 1-1002 as set forth below:
composition comprising any one of the compounds of formulae (IA)-(IH) for use in the treatment of a neurodegenerative disorder, such as tauopathies.
compositions of the invention may comprise, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
a pharmaceutically acceptable excipient e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.
compositions for oral administration may be in tablet, capsule, powder or liquid form.
a tablet may include a solid carrier such as gelatin or an adjuvant.
Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.
Physiological saline solution dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
the compounds of formulae (IA)-(IH) are believed to be casein kinase 1 delta (CK1 ⁇ ) inhibitors.
Certain compounds of formulae (IA)-(IH) have inhibitory activity of greater than 5%, in particular greater than 10%, more particularly greater than 25%, yet more particularly greater than 50%, especially greater than 75%, such as greater than 90%.
Such compounds may be useful in the treatment in neurodegenerative disorders such as tauopathies.
Tauopathies are conditions which are characterised by neurofibrillary tangles or aggregates of the tau protein.
Tauopathies are a recognised class of conditions known to those skilled in the art and include Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neurobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Straussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex
the intracellular tau deposits are usually neuronal or glial and are filamentous and generally in a hyperphosphorylated state as compared to the level of phosphorylation in tau from control human brain.
this hyperphosphorylated tau is often referred to a paired helical filament tau (PHF) tau because it is derived from the PHF.
the tauopathy comprises Alzheimer's disease.
a method of treating a neurodegenerative disorder such as tauopathies, which comprises administering a therapeutically effective amount of a compound of formulae (IA)-(IH).
the compounds of the invention may be tested for inhibition of casein kinase 1 delta (CK1 ⁇ ) in accordance with the assay protocols described in US 2010/0152157, EP 1,636,375 or Hanger et al (2007) J. Biol. Chem. 282, 23645-23654.
the assay was conducted in accordance with the following protocol :
Base Reaction buffer 20 mM Hepes (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT, 1% DMSO It should be noted that required cofactors are added individually to each kinase reaction.
Recombinant human full-length construct GST-tagged, expressed in insect cells.
compounds 10, 324, 654, 856, 859, 931, 947, 952, 987, 990 and 999 exhibited inhibition of greater than 90%.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Pyrane Compounds (AREA)

US13/993,288 2010-12-14 2011-12-14 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES Abandoned US20140031547A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB1021161.3A GB201021161D0 (en)	2010-12-14	2010-12-14	Casein kinase 1delta (CK1Delta) inhibitors
GB1021161.3		2010-12-14
GB1109162.6		2011-06-01
GBGB1109162.6A GB201109162D0 (en)	2011-06-01	2011-06-01	Casein kinase 1Delta (CK1Delta) inhibitors
PCT/GB2011/052475 WO2012080729A2 (en)	2010-12-14	2011-12-14	CASEIN KINASE 1δ (CK1δ) INHIBITORS

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/GB2011/052475 A-371-Of-International WO2012080729A2 (en)	2010-12-14	2011-12-14	CASEIN KINASE 1δ (CK1δ) INHIBITORS

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US15/171,582 Division US20160354375A1 (en)	2010-12-14	2016-06-02	CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

Publications (1)

Publication Number	Publication Date
US20140031547A1 true US20140031547A1 (en)	2014-01-30

Family

ID=45444638

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
US13/993,288 Abandoned US20140031547A1 (en)	2010-12-14	2011-12-14	CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US13/993,303 Abandoned US20140018540A1 (en)	2010-12-14	2011-12-14	Casein kinase 1delta (ck 1delta) inhibitors
US14/677,273 Active US9789111B2 (en)	2010-12-14	2015-04-02	Casein kinase 1δ (CK 1δ) inhibitors
US14/842,155 Active US9763947B2 (en)	2010-12-14	2015-09-01	Casein kinase 1delta (CK1delta) inhibitors
US15/171,582 Abandoned US20160354375A1 (en)	2010-12-14	2016-06-02	CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
US13/993,303 Abandoned US20140018540A1 (en)	2010-12-14	2011-12-14	Casein kinase 1delta (ck 1delta) inhibitors
US14/677,273 Active US9789111B2 (en)	2010-12-14	2015-04-02	Casein kinase 1δ (CK 1δ) inhibitors
US14/842,155 Active US9763947B2 (en)	2010-12-14	2015-09-01	Casein kinase 1delta (CK1delta) inhibitors
US15/171,582 Abandoned US20160354375A1 (en)	2010-12-14	2016-06-02	CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

Country Status (10)

Country	Link
US (5)	US20140031547A1 (ja)
EP (3)	EP2835131B1 (ja)
JP (4)	JP2014503528A (ja)
CN (3)	CN105920010A (ja)
AU (2)	AU2011343039B2 (ja)
CA (1)	CA2818903C (ja)
DK (1)	DK2835131T3 (ja)
ES (2)	ES2650744T3 (ja)
HK (2)	HK1190622A1 (ja)
WO (2)	WO2012080727A2 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8809349B2 (en)	2011-01-10	2014-08-19	Infinity Pharmaceuticals, Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9206182B2 (en)	2009-07-15	2015-12-08	Intellikine Llc	Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9328096B2 (en)	2014-05-07	2016-05-03	Pfizer Inc.	Tropomyosin-related kinase inhibitors
US9815841B2 (en)	2014-01-29	2017-11-14	Glaxosmithkline Intellectual Property Development Limited	Compounds
US9822131B2 (en)	2008-01-04	2017-11-21	Intellikine Llc	Certain chemical entities, compositions and methods
US9868749B2 (en) *	2013-12-09	2018-01-16	Ucb Biopharma Sprl	Fused imidazole and pyrazole derivatives as modulators of TNF activity
WO2018030762A1 (ko) *	2016-08-09	2018-02-15	세종대학교산학협력단	Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물
US10087186B2 (en)	2014-01-29	2018-10-02	Glaxosmithkline Intellectual Property Development Limited	Compounds as LRRK2 kinase inhibitors
US10357489B2 (en)	2017-07-10	2019-07-23	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US10709714B2 (en)	2013-11-22	2020-07-14	Clifton Life Sciences LLC	Gastrin antagonists for treatment and prevention of osteoporosis
US10894797B2 (en)	2018-09-18	2021-01-19	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US10947242B2 (en)	2016-11-02	2021-03-16	Janssen Pharmaceutica, Nv	[1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
US10947239B2 (en)	2015-11-02	2021-03-16	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
US11053248B2 (en)	2016-11-02	2021-07-06	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
US11110096B2 (en)	2014-04-16	2021-09-07	Infinity Pharmaceuticals, Inc.	Combination therapies
US11147818B2 (en)	2016-06-24	2021-10-19	Infinity Pharmaceuticals, Inc.	Combination therapies
US11319321B2 (en)	2016-11-02	2022-05-03	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
US11613548B2 (en)	2021-02-19	2023-03-28	Sudo Biosciences Limited	Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
US12084458B2 (en)	2021-02-19	2024-09-10	Sudo Biosciences Limited	Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE032813T2 (en)	2005-12-28	2017-11-28	Vertex Pharma	Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
MX2011013816A (es)	2009-06-29	2012-04-11	Incyte Corp	Pirimidinonas como inhibidores de pi3k.
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
US20130018039A1 (en) *	2010-03-31	2013-01-17	Bodmer Vera Q	Imidazolyl-imidazoles as kinase inhibitors
US9193721B2 (en)	2010-04-14	2015-11-24	Incyte Holdings Corporation	Fused derivatives as PI3Kδ inhibitors
WO2011163195A1 (en)	2010-06-21	2011-12-29	Incyte Corporation	Fused pyrrole derivatives as pi3k inhibitors
JP2014503528A (ja) *	2010-12-14	2014-02-13	エレクトロプホレトイクスリミテッド	カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
CA2822070C (en)	2010-12-20	2019-09-17	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201104267D0 (en)	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AR087701A1 (es)	2011-08-31	2014-04-09	Japan Tobacco Inc	Derivados de pirazol con actividad inhibidora de sglt1
DK2751109T3 (en)	2011-09-02	2017-01-23	Incyte Holdings Corp	HETEROCYCLYLAMINES AS PI3K INHIBITORS
PE20141120A1 (es)	2011-10-07	2014-09-15	Takeda Pharmaceutical	Compuestos heterociclicos
BR112014009524A2 (pt)	2011-10-18	2017-05-09	Astellas Pharma Inc	composto heterocíclico bicíclico
AR090037A1 (es)	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
JP6141864B2 (ja)	2011-12-01	2017-06-07	ケモセントリックス，インコーポレイティド	Ｃｃｒ（４）アンタゴニストとしての置換アニリン
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013186159A1 (en)	2012-06-13	2013-12-19	F. Hoffmann-La Roche Ag	New diazaspirocycloalkane and azaspirocycloalkane
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014007228A1 (ja) *	2012-07-03	2014-01-09	小野薬品工業株式会社	ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
WO2014009891A1 (en) *	2012-07-11	2014-01-16	Piramal Enterprises Limited	Heterocyclic compounds for use in the treatment of cancers
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN104736202B (zh)	2012-08-22	2021-09-07	康奈尔大学	用于抑制肌成束蛋白的方法
US9328078B2 (en) *	2012-08-24	2016-05-03	Treventis Corporation	Benzofurazan anti-amyloid compounds and methods
CN102850341B (zh) *	2012-09-05	2015-02-18	浙江工业大学	一种噻二唑类化合物及其制备与应用
GB201216018D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Pharmacologically active compounds
IN2015DN00960A (ja)	2012-09-25	2015-06-12	Hoffmann La Roche
CN103739594A (zh) *	2012-10-17	2014-04-23	南京大学	一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
WO2014084778A1 (en)	2012-11-27	2014-06-05	Thomas Helledays Stiftelse För Medicinsk Forskning	Pyrimidine-2,4-diamine derivatives for treatment of cancer
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
EP2939675B1 (en) *	2012-12-28	2019-09-04	Shin Nippon Biomedical Laboratories, Ltd.	Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
NZ710444A (en)	2013-02-11	2020-08-28	Univ California	Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
AR095079A1 (es)	2013-03-12	2015-09-16	Hoffmann La Roche	Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JP2016520532A (ja)	2013-03-15	2016-07-14	ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ	ベンゾイミダゾール誘導体およびその使用
EP2970306A4 (en) *	2013-03-15	2016-08-03	Epizyme Inc	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
US9045477B2 (en)	2013-03-15	2015-06-02	Epizyme, Inc.	Substituted 6,5-fused bicyclic heteroaryl compounds
SI2986610T1 (en)	2013-04-19	2018-04-30	Incyte Holdings Corporation	Bicyclic heterocycles as inhibitors of FGFR
US9797882B2 (en)	2013-07-09	2017-10-24	The Translational Genomics Research Institute	Method of screening for a compound for inhibitory activity of FN14-tweak interaction
EP3019874B1 (en) *	2013-07-09	2019-08-21	The Translational Genomics Research Institute	Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14
TWI649308B (zh)	2013-07-24	2019-02-01	小野藥品工業股份有限公司	喹啉衍生物
GB201314452D0 (en)	2013-08-13	2013-09-25	Ostara Biomedical Ltd	Embryo implantation
RU2570907C2 (ru) *	2013-10-21	2015-12-20	Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан"	Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
UA118201C2 (uk)	2013-11-26	2018-12-10	Ф. Хоффманн-Ля Рош Аг	НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
WO2015106025A1 (en) *	2014-01-09	2015-07-16	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Substituted benzoxazine and related compounds
EP3104706B1 (en)	2014-02-11	2022-03-23	Mitokinin, Inc.	Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
ME03580B (me)	2014-02-13	2020-07-20	Incyte Corp	Ciklopropilamini kao lsd1 inhibitori
US9493442B2 (en)	2014-02-13	2016-11-15	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
AU2015217073B2 (en)	2014-02-13	2019-08-22	Incyte Holdings Corporation	Cyclopropylamines as LSD1 inhibitors
DK3107902T3 (da)	2014-02-20	2021-05-03	Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec	Forbindelser og fremgangsmåder til at hæmme fascin
PT3110812T (pt) *	2014-02-27	2019-07-10	Treventis Corp	Compostos antiamiloide contendo benzofurazano
RS59477B1 (sr)	2014-03-26	2019-12-31	Hoffmann La Roche	Biciklička jedinjenja kao inhibitori proizvodnje autotaksina (atx) i lizofosfatidne kiseline (lpa)
EA032357B1 (ru)	2014-03-26	2019-05-31	Ф. Хоффманн-Ля Рош Аг	Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
US20170029388A1 (en) *	2014-04-11	2017-02-02	Intercontinental Great Brands Llc	Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto
WO2015158313A1 (en) *	2014-04-19	2015-10-22	Sunshine Lake Pharma Co., Ltd.	Sulfonamide derivatives and pharmaceutical applications thereof
PT3597649T (pt)	2014-04-23	2022-01-21	Dart Neuroscience Llc	Composições contendo compostos substituidos de [1,2,4]triazolo[1,5-a] pirimidin-7il como inibidores de pde2
CN104059060B (zh) *	2014-05-30	2017-08-01	西安交通大学	一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
SG11201609981RA (en)	2014-06-04	2016-12-29	Thomas Helledays Stiftelse För Medicinsk Forskning	Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
CA2949785A1 (en)	2014-06-04	2015-12-10	Thomas Helledays Stiftelse For Medicinsk Forskning	Mth1 inhibitors for treatment of cancer
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
SG11201700140TA (en) *	2014-07-31	2017-02-27	Merck Patent Gmbh	Indolizine derivatives which are applicable to neurodegenerative diseases
WO2016022465A1 (en) *	2014-08-04	2016-02-11	Drexel University	Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
ES2702288T3 (es)	2014-10-07	2019-02-28	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
GB201419579D0 (en) *	2014-11-03	2014-12-17	Iomet Pharma Ltd	Pharmaceutical compound
WO2016073424A1 (en)	2014-11-05	2016-05-12	Dart Neuroscience, Llc	Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
JP6708130B2 (ja)	2014-12-25	2020-06-10	小野薬品工業株式会社	キノリン誘導体
GB201501302D0 (en)	2015-01-27	2015-03-11	Ostara Biomedical Ltd	Embryo implantation
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
SG10201913036RA (en)	2015-02-20	2020-02-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
RS63963B1 (sr)	2015-02-27	2023-03-31	Incyte Holdings Corp	Postupak pripreme pi3k inhibitora
WO2016149756A1 (en)	2015-03-23	2016-09-29	The University Of Melbourne	Treatment of respiratory diseases
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
MA41898A (fr)	2015-04-10	2018-02-13	Hoffmann La Roche	Dérivés de quinazolinone bicyclique
AU2016254049A1 (en) *	2015-04-30	2017-11-02	Musc Foundation For Research Development	Oxindole compounds and pharmaceutical compositions thereof
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
GB201508276D0 (en) *	2015-05-14	2015-06-24	Electrophoretics Ltd	A casein kinase 1 delta inhibitor
EP3303332A1 (en) *	2015-06-01	2018-04-11	Bantam Pharmaceutical, LLC	Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
WO2016202758A1 (en)	2015-06-18	2016-12-22	Bayer Pharma Aktiengesellschaft	Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202756A1 (en)	2015-06-18	2016-12-22	Bayer Pharma Aktiengesellschaft	Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2017000277A1 (en) *	2015-07-01	2017-01-05	Merck Sharp & Dohme Corp.	Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017004405A1 (en)	2015-07-01	2017-01-05	Northwestern University	Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
PE20181175A1 (es)	2015-08-12	2018-07-20	Incyte Corp	Sales de un inhibidor de lsd1
CN105061462B (zh) *	2015-08-18	2017-05-24	沈阳药科大学	含有酰胺的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CR20180058A (es) *	2015-09-04	2018-02-26	Hoffmann La Roche	Nuevos derivados de fenoximetilo
MX2018003318A (es)	2015-09-18	2018-05-16	Kaken Pharma Co Ltd	Derivado de biarilo y medicamento que contiene el mismo.
PE20180451A1 (es)	2015-09-24	2018-03-05	Hoffmann La Roche	Nuevos compuestos biciclicos como inhibidores de atx
WO2017050791A1 (en)	2015-09-24	2017-03-30	F. Hoffmann-La Roche Ag	New bicyclic compounds as dual atx/ca inhibitors
PE20180461A1 (es)	2015-09-24	2018-03-06	Hoffmann La Roche	Nuevos compuestos biciclicos como inhibidores de la atx
PE20180233A1 (es)	2015-09-24	2018-01-31	Hoffmann La Roche	Nuevos compuestos biciclicos como inhibidores duales de atx / ca
GB201517523D0 (en)	2015-10-05	2015-11-18	Ostara Biomedical Ltd	Methods and compositions for managing reproduction
US20190112317A1 (en)	2015-10-05	2019-04-18	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017063966A1 (en)	2015-10-13	2017-04-20	Bayer Pharma Aktiengesellschaft	Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
CN106831570B (zh) *	2015-12-07	2020-03-31	成都海创药业有限公司	喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
US20200375996A1 (en) *	2015-12-15	2020-12-03	D.E. Shaw Research, Llc	Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
CN107033087B (zh) *	2016-02-04	2020-09-04	西华大学	1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
WO2017133258A1 (zh) *	2016-02-04	2017-08-10	西华大学	1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107840826B (zh) *	2016-09-19	2021-07-09	西华大学	1h-吲唑类衍生物及其作为ido抑制剂的用途
AU2017252328B2 (en)	2016-04-22	2023-02-23	Incyte Corporation	Formulations of an LSD1 inhibitor
WO2017210545A1 (en)	2016-06-02	2017-12-07	Cadent Therapeutics, Inc.	Potassium channel modulators
KR20230109185A (ko)	2016-06-07	2023-07-19	자코바이오 파마슈티칼스 컴퍼니 리미티드	Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
WO2018011681A1 (en)	2016-07-14	2018-01-18	Pfizer Inc.	Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JP7471818B2 (ja)	2016-08-18	2024-04-22	ヴィダックファーマリミテッド	ピペラジン誘導体、医薬組成物、及びその使用方法
LT3507291T (lt)	2016-09-02	2021-09-10	Cyclerion Therapeutics, Inc.	Kondensuoti bicikliniai sgc stimuliatoriai
CN106432235B (zh) *	2016-10-19	2018-02-02	南通大学	靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途
MA46589A (fr)	2016-10-24	2019-08-28	Yumanity Therapeutics Inc	Composés et utilisations de ces derniers
US11008325B2 (en)	2016-11-14	2021-05-18	Virginia Commonwealth University	Inhibitors of cancer invasion, attachment, and/or metastasis
EP3541378A4 (en) *	2016-11-16	2020-10-07	University of South Florida	ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE RELIEF OF PROTEINOPATHIA
US11628159B2 (en) *	2017-01-10	2023-04-18	Eth Zurich	Cell-protective compounds and their use
CN110198935B (zh)	2017-01-23	2022-05-31	卡登特治疗公司	钾通道调节剂
CN106748969B (zh) *	2017-01-23	2019-06-18	南阳师范学院	一种n-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途
CN106831573B (zh) *	2017-01-23	2019-05-24	南阳师范学院	(n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
SG11201906819VA (en)	2017-01-26	2019-08-27	Ono Pharmaceutical Co	Ethane-sulfonate salt of quinoline derivative
IL268128B2 (en)	2017-02-01	2023-03-01	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	n1-(4-(5-(cyclopropylmethyl)-1-methyl-1-h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or Iraki inhibitors for cancer therapy
CN109846879B (zh) *	2017-03-01	2021-06-29	浙江大学	亚胺结构类型雄激素受体拮抗剂及其应用
BR112019019017A2 (pt)	2017-03-16	2020-04-14	Hoffmann La Roche	compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
CN110382484B (zh)	2017-03-16	2022-12-06	豪夫迈·罗氏有限公司	新的作为atx抑制剂的二环化合物
MD3483164T2 (ro)	2017-03-20	2020-07-31	Forma Therapeutics Inc	Compoziții pirolopirolice ca activatori ai piruvat kinazei (PKR)
FI3601239T3 (fi)	2017-03-23	2024-09-11	Jacobio Pharmaceuticals Co Ltd	Uusia heterosyklisiä johdannaisia, jotka ovat käyttökelpoisia SHP2-inhibiittoreina
EP3615529B1 (en)	2017-04-26	2024-06-05	Basilea Pharmaceutica International AG, Allschwil	Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
JP7343170B2 (ja) *	2017-05-12	2023-09-12	ボードオブトラスティーズオブザサザンイリノイユニバーシティオンビハーフオブサザンイリノイユニバーシティエドワーズビル	３，４，５－三置換－１，２，４－トリアゾールおよび３，４，５－三置換－３－チオ－１，２，４－トリアゾール、ならびにそれらの使用
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JOP20190282A1 (ar)	2017-06-09	2019-12-05	Novartis Ag	مركبات وتركيبات لحث تكوّن الغضاريف
CN110997664A (zh) *	2017-06-14	2020-04-10	欧洲分子生物学实验室	用于疗法的苯并呋喃酰胺及其杂芳族类似物
EP3641545A4 (en)	2017-06-21	2021-02-24	Mitokinin, Inc.	COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
GB201710851D0 (en) *	2017-07-06	2017-08-23	Galápagos Nv	Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
UY37806A (es)	2017-07-11	2020-01-31	Vertex Pharma	Carboxamidas como moduladores de los canales de sodio
US20200277272A1 (en) *	2017-09-11	2020-09-03	Hodogaya Chemical Co., Ltd.	Compound having pyrimidine ring structure and organic electroluminescence device
WO2019055869A1 (en)	2017-09-15	2019-03-21	Forma Therapeutics, Inc.	TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
JP7223998B2 (ja)	2017-10-13	2023-02-17	小野薬品工業株式会社	Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
IL273839B (en)	2017-10-19	2022-09-01	Amgen Inc	Benzimidazole derivatives and their uses
WO2019084157A1 (en)	2017-10-24	2019-05-02	Yumanity Therapeutics, Inc.	COMPOUNDS AND USES THEREOF
JP2021507944A (ja) *	2017-12-21	2021-02-25	グリアファームエスエー	運動ニューロン疾患を含む神経障害のための組成物および治療方法
MX2020006385A (es) *	2017-12-21	2020-12-07	Gliapharm Sa	Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
JP7474709B2 (ja)	2018-02-27	2024-04-25	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
US20210040074A1 (en) *	2018-03-06	2021-02-11	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Positive allosteric modulators of dopamine 1 receptor and method of use thereof
EP3543231A1 (en) *	2018-03-19	2019-09-25	ETH Zurich	Compounds for treating cns- and neurodegenerative diseases
EP3788046A1 (en)	2018-05-04	2021-03-10	Incyte Corporation	Salts of an fgfr inhibitor
WO2019213544A2 (en)	2018-05-04	2019-11-07	Incyte Corporation	Solid forms of an fgfr inhibitor and processes for preparing the same
TWI815887B (zh) *	2018-05-15	2023-09-21	美商愛彼特生物製藥股份有限公司	經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
MA52940A (fr)	2018-05-18	2021-04-28	Incyte Corp	Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
GB201810581D0 (en)	2018-06-28	2018-08-15	Ctxt Pty Ltd	Compounds
CN112513038B (zh)	2018-06-29	2023-01-10	福马疗法公司	抑制creb结合蛋白(cbp)
AU2019297361B2 (en)	2018-07-05	2024-06-27	Incyte Corporation	Fused pyrazine derivatives as A2A / A2B inhibitors
CN112805000A (zh) *	2018-08-06	2021-05-14	小利兰·斯坦福大学董事会	作为ppargc1a激活剂用于治疗神经退行性疾病的2-芳基苯并咪唑
SG11202101454PA (en)	2018-08-29	2021-03-30	Chemocentryx Inc	Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
US11278527B2 (en)	2018-09-04	2022-03-22	Brown University	Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder
CN113226356A (zh)	2018-09-19	2021-08-06	福马治疗股份有限公司	活化丙酮酸激酶r
CN113166060B (zh)	2018-09-19	2024-01-09	诺沃挪第克健康护理股份公司	用丙酮酸激酶激活化合物治疗镰状细胞病
EP3870291A1 (en)	2018-10-22	2021-09-01	Cadent Therapeutics, Inc.	Crystalline forms of potassium channel modulators
CN109503563B (zh) *	2018-12-10	2020-05-12	济南大学	多功能乙酰胆碱酯酶抑制剂及其应用
KR102128509B1 (ko) *	2018-12-19	2020-07-01	한국과학기술연구원	말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
CN113286785A (zh) *	2019-01-04	2021-08-20	贝尔布鲁克实验室有限责任公司	作为治疗剂的cGAS活性的抑制剂
US12098146B2 (en)	2019-01-24	2024-09-24	Janssen Pharmaceutica Nv	Compounds and uses thereof
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
JP7546596B2 (ja)	2019-04-26	2024-09-06	セルジーンコーポレーション	ヘテロ環式化合物ならびに蠕虫感染および疾患におけるその使用
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
JP7352662B2 (ja)	2019-06-18	2023-09-28	ファイザー・インク	ベンゾイソオキサゾールスルホンアミド誘導体
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
RU2746423C2 (ru) *	2019-09-02	2021-04-13	Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар")	Ингибитор вируса гепатита В (ВГВ)
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja)	2019-10-14	2022-12-15	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4066832A4 (en) *	2019-11-14	2024-01-03	Zincure Corp.	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLERosis BASED ON AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
US11897891B2 (en)	2019-12-04	2024-02-13	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
PE20230300A1 (es)	2019-12-06	2023-02-13	Vertex Pharma	Tetrahidrofuranos sustituidos como moduladores de canales de sodio
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
AR122711A1 (es) *	2020-06-25	2022-09-28	Alchemedicine Inc	COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
JP2023541463A (ja) *	2020-09-17	2023-10-02	ヤンセンファーマシューティカエヌ．ベー．	カゼインキナーゼ１デルタモジュレーター
US11795168B2 (en)	2020-09-23	2023-10-24	Forma Therapeutics, Inc.	Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en)	2020-09-23	2023-10-31	Forma Therapeutics, Inc.	Bromodomain inhibitors for androgen receptor-driven cancers
US12128035B2 (en)	2021-03-19	2024-10-29	Novo Nordisk Health Care Ag	Activating pyruvate kinase R
CA3215903A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
PE20241335A1 (es)	2021-06-04	2024-07-03	Vertex Pharma	N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN115466211B (zh) *	2022-06-09	2024-02-23	中国人民解放军空军军医大学	一种n-苯基喹啉-4-胺类化合物及其应用
WO2024012554A1 (zh) *	2022-07-14	2024-01-18	上海日馨医药科技股份有限公司	Tpk激动剂及使用其治疗神经退行性疾病的方法
WO2024155864A1 (en) *	2023-01-20	2024-07-25	Allianthera (Suzhou) Biopharmaceutical Co., Ltd.	Sprk1 inhibitors and methods of use
WO2024159285A1 (pt) *	2023-01-30	2024-08-08	Eurofarma Laboratórios S.A.	Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
WO2024159286A1 (pt) *	2023-01-30	2024-08-08	Eurofarma Laboratórios S.A.	Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000012497A2 (en) *	1998-08-28	2000-03-09	Scios Inc.	Quinazoline derivatives as medicaments
WO2004078733A1 (en) *	2003-03-03	2004-09-16	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
WO2005099711A1 (en) *	2004-04-13	2005-10-27	Icagen, Inc.	Polycyclic pyrimidines as potassium ion channel modulators

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9506197D0 (en)	1995-03-27	1995-05-17	Hoffmann La Roche	Inhibition of tau-tau association.
US5545656A (en) *	1995-04-05	1996-08-13	Pfizer Inc.	2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US20030219427A1 (en) *	1998-08-18	2003-11-27	Allen Hamish J.	TPL-2/COT kinase and methods of use
US6087363A (en) *	1999-07-16	2000-07-11	Harbor Branch Oceanographic Institution, Inc.	Use of imidazole and indole compounds as inhibitors of nitric oxide synthase
SI1315731T1 (en) *	2000-09-01	2005-02-28	Sanofi-Aventis	2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1h)one derivatives
IL154747A0 (en) *	2000-09-15	2003-10-31	Vertex Pharma	Pyrazole derivatives and pharmaceutical compositions containing the same
US7045539B2 (en) *	2000-12-22	2006-05-16	Astrazeneca Ab	Therapeutic benzoxazole compounds
ES2295441T3 (es) *	2001-12-18	2008-04-16	MERCK & CO., INC.	Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
JP2003212859A (ja) *	2002-01-24	2003-07-30	Nippon Nohyaku Co Ltd	置換フェニルヘテロ環類及びこれを有効成分とする除草剤
JP2005530707A (ja) *	2002-03-08	2005-10-13	イーライ・リリー・アンド・カンパニー	キナーゼ阻害物質
FR2836915B1 (fr) *	2002-03-11	2008-01-11	Aventis Pharma Sa	Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US20040038856A1 (en) *	2002-05-17	2004-02-26	Sarvajit Chakravarty	Treatment of fibroproliferative disorders using TGF-beta inhibitors
WO2003106439A1 (ja) *	2002-06-12	2003-12-24	株式会社ビーエフ研究所	アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
US7060698B2 (en) *	2003-05-19	2006-06-13	Hoffmann-La Roche Inc.	Benzoxazepinone derivatives
US20060241150A1 (en) *	2003-06-06	2006-10-26	Weiner David B	P38 kinase inhibitor compositions and methods of using the same
GB0314943D0 (en)	2003-06-25	2003-07-30	Proteome Sciences Plc	Screening methods
PL1791537T3 (pl) *	2004-08-19	2010-04-30	Aventis Pharma Inc	Pochodne 3-arylotioindolo-2-karboksamidów i ich analogi jako inhibitory kinazy kazeinowej I
WO2007015866A2 (en) *	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
EP1842541A1 (en) *	2006-03-29	2007-10-10	G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg	Plant components and extracts and uses thereof
TW200813035A (en) *	2006-06-19	2008-03-16	Astrazeneca Ab	Novel heteroaryl substituted benzoxazoles
MX2008015648A (es) *	2006-06-21	2009-01-09	Du Pont	Pirazinonas como inhibidores de proliferacion celular.
US7622495B2 (en) *	2006-10-03	2009-11-24	Neurim Pharmaceuticals (1991) Ltd.	Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
CA2668454A1 (en) *	2006-11-02	2008-05-08	F. Hoffmann-La Roche Ag	Substituted 2-imidazoles
US8362066B2 (en) *	2006-11-17	2013-01-29	Treventis Corporation	Compounds and methods for treating protein folding disorders
WO2008077138A1 (en) *	2006-12-19	2008-06-26	The Board Of Trustees Of The University Of Illinois	3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
WO2008156715A1 (en) *	2007-06-20	2008-12-24	Merck & Co., Inc.	Cetp inhibitors derived from benzoxazole arylamides
FR2918061B1 (fr) *	2007-06-28	2010-10-22	Sanofi Aventis	Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) *	2007-07-19	2009-09-04	Sanofi Aventis Sa	Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
GB0715939D0 (en) *	2007-08-15	2007-09-26	Vastox Plc	Method of treatment of duchenne muscular dystrophy
US20110065715A1 (en) *	2007-11-28	2011-03-17	Yale University	Nogo Receptor Binding Small Molecules to Promote Axonal Growth
CA2709784A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
EP2149551A1 (de) *	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
FR2934994B1 (fr) *	2008-08-12	2010-09-17	Sanofi Aventis	Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
KR101257695B1 (ko) *	2008-12-24	2013-04-24	제일모직주식회사	신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
FR2945289A1 (fr) *	2009-05-11	2010-11-12	Sanofi Aventis	Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
EP2528441A4 (en) *	2010-01-25	2013-07-10	Chdi Foundation Inc	CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
JP2014503528A (ja) *	2010-12-14	2014-02-13	エレクトロプホレトイクスリミテッド	カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
WO2012154814A1 (en)	2011-05-09	2012-11-15	Eip Pharma, Llc	Compositions and methods for treating alzheimer's disease

2011
- 2011-12-14 JP JP2013543881A patent/JP2014503528A/ja active Pending
- 2011-12-14 EP EP14190691.7A patent/EP2835131B1/en not_active Not-in-force
- 2011-12-14 JP JP2013543879A patent/JP5937102B2/ja not_active Expired - Fee Related
- 2011-12-14 DK DK14190691.7T patent/DK2835131T3/en active
- 2011-12-14 EP EP11804754.7A patent/EP2651404B1/en not_active Not-in-force
- 2011-12-14 ES ES14190691.7T patent/ES2650744T3/es active Active
- 2011-12-14 US US13/993,288 patent/US20140031547A1/en not_active Abandoned
- 2011-12-14 CN CN201610264700.0A patent/CN105920010A/zh active Pending
- 2011-12-14 EP EP11804755.4A patent/EP2651405A2/en not_active Withdrawn
- 2011-12-14 CN CN201180060132.8A patent/CN103298460B/zh not_active Expired - Fee Related
- 2011-12-14 CA CA2818903A patent/CA2818903C/en active Active
- 2011-12-14 CN CN201510246272.4A patent/CN104906103B/zh not_active Expired - Fee Related
- 2011-12-14 US US13/993,303 patent/US20140018540A1/en not_active Abandoned
- 2011-12-14 ES ES11804754.7T patent/ES2553610T3/es active Active
- 2011-12-14 WO PCT/GB2011/052473 patent/WO2012080727A2/en active Application Filing
- 2011-12-14 AU AU2011343039A patent/AU2011343039B2/en not_active Ceased
- 2011-12-14 WO PCT/GB2011/052475 patent/WO2012080729A2/en active Application Filing
2014
- 2014-04-22 HK HK14103807.1A patent/HK1190622A1/zh not_active IP Right Cessation
2015
- 2015-04-02 US US14/677,273 patent/US9789111B2/en active Active
- 2015-09-01 US US14/842,155 patent/US9763947B2/en active Active
2016
- 2016-03-07 HK HK16102571.5A patent/HK1214527A1/zh unknown
- 2016-05-11 JP JP2016095027A patent/JP6243472B2/ja active Active
- 2016-06-02 US US15/171,582 patent/US20160354375A1/en not_active Abandoned
- 2016-09-08 JP JP2016175298A patent/JP2017025080A/ja not_active Withdrawn
2017
- 2017-02-06 AU AU2017200812A patent/AU2017200812B2/en not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000012497A2 (en) *	1998-08-28	2000-03-09	Scios Inc.	Quinazoline derivatives as medicaments
WO2004078733A1 (en) *	2003-03-03	2004-09-16	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
WO2005099711A1 (en) *	2004-04-13	2005-10-27	Icagen, Inc.	Polycyclic pyrimidines as potassium ion channel modulators

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11433065B2 (en)	2008-01-04	2022-09-06	Intellikine Llc	Certain chemical entities, compositions and methods
US9822131B2 (en)	2008-01-04	2017-11-21	Intellikine Llc	Certain chemical entities, compositions and methods
US9655892B2 (en)	2008-01-04	2017-05-23	Intellikine Llc	Certain chemical entities, compositions and methods
US9216982B2 (en)	2008-01-04	2015-12-22	Intellikine Llc	Certain chemical entities, compositions and methods
US9522146B2 (en)	2009-07-15	2016-12-20	Intellikine Llc	Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en)	2009-07-15	2015-12-08	Intellikine Llc	Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9290497B2 (en)	2011-01-10	2016-03-22	Infinity Pharmaceuticals, Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
US10550122B2 (en)	2011-01-10	2020-02-04	Infinity Pharmaceuticals, Inc.	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US11312718B2 (en)	2011-01-10	2022-04-26	Infinity Pharmaceuticals, Inc.	Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
USRE46621E1 (en)	2011-01-10	2017-12-05	Infinity Pharmaceuticals, Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en)	2011-01-10	2017-12-12	Infinity Pharmaceuticals, Inc.	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US8809349B2 (en)	2011-01-10	2014-08-19	Infinity Pharmaceuticals, Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9527847B2 (en)	2012-06-25	2016-12-27	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US10709714B2 (en)	2013-11-22	2020-07-14	Clifton Life Sciences LLC	Gastrin antagonists for treatment and prevention of osteoporosis
US9868749B2 (en) *	2013-12-09	2018-01-16	Ucb Biopharma Sprl	Fused imidazole and pyrazole derivatives as modulators of TNF activity
US9815841B2 (en)	2014-01-29	2017-11-14	Glaxosmithkline Intellectual Property Development Limited	Compounds
US10618901B2 (en)	2014-01-29	2020-04-14	Glaxosmithkline Intellectual Property Development Limited	LRRK2 inhibitors for the treatment of Parkinson's disease
US10087186B2 (en)	2014-01-29	2018-10-02	Glaxosmithkline Intellectual Property Development Limited	Compounds as LRRK2 kinase inhibitors
US11944631B2 (en)	2014-04-16	2024-04-02	Infinity Pharmaceuticals, Inc.	Combination therapies
US11110096B2 (en)	2014-04-16	2021-09-07	Infinity Pharmaceuticals, Inc.	Combination therapies
US9328096B2 (en)	2014-05-07	2016-05-03	Pfizer Inc.	Tropomyosin-related kinase inhibitors
US10947239B2 (en)	2015-11-02	2021-03-16	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
US11147818B2 (en)	2016-06-24	2021-10-19	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2018030762A1 (ko) *	2016-08-09	2018-02-15	세종대학교산학협력단	Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물
US11053248B2 (en)	2016-11-02	2021-07-06	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
US10947242B2 (en)	2016-11-02	2021-03-16	Janssen Pharmaceutica, Nv	[1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
US11319321B2 (en)	2016-11-02	2022-05-03	Janssen Pharmaceutica Nv	[1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
US12029738B2 (en)	2017-07-10	2024-07-09	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US10675281B2 (en)	2017-07-10	2020-06-09	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US11185543B2 (en)	2017-07-10	2021-11-30	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US10357489B2 (en)	2017-07-10	2019-07-23	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US10894797B2 (en)	2018-09-18	2021-01-19	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11518772B2 (en)	2018-09-18	2022-12-06	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en)	2018-09-18	2022-10-04	Nikang Therapeutics, Inc.	Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11034705B2 (en)	2018-09-18	2021-06-15	Nikang Therapeutics, Inc.	Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11613548B2 (en)	2021-02-19	2023-03-28	Sudo Biosciences Limited	Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
US12084458B2 (en)	2021-02-19	2024-09-10	Sudo Biosciences Limited	Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12103937B2 (en)	2021-02-19	2024-10-01	Sudo Biosciences Limited	Substituted pyridines and pyridazines as TYK2 inhibitors
US12122785B2 (en)	2021-02-19	2024-10-22	Sudo Biosciences Limited	Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Also Published As

Publication number	Publication date
HK1214527A1 (zh)	2016-07-29
US20140018540A1 (en)	2014-01-16
JP5937102B2 (ja)	2016-06-22
EP2651404B1 (en)	2015-10-14
EP2835131B1 (en)	2017-09-06
WO2012080727A2 (en)	2012-06-21
JP2014503527A (ja)	2014-02-13
EP2651405A2 (en)	2013-10-23
WO2012080729A4 (en)	2012-11-08
WO2012080727A4 (en)	2012-10-26
WO2012080727A3 (en)	2012-08-23
WO2012080729A2 (en)	2012-06-21
ES2553610T3 (es)	2015-12-10
US9789111B2 (en)	2017-10-17
CA2818903C (en)	2021-03-23
EP2835131A1 (en)	2015-02-11
AU2011343039A1 (en)	2013-06-27
CN104906103A (zh)	2015-09-16
DK2835131T3 (en)	2017-12-04
CN103298460A (zh)	2013-09-11
JP2014503528A (ja)	2014-02-13
US20160354375A1 (en)	2016-12-08
CN105920010A (zh)	2016-09-07
CN103298460B (zh)	2016-06-01
CA2818903A1 (en)	2012-06-21
WO2012080729A3 (en)	2012-08-02
CN104906103B (zh)	2018-05-18
JP2016172757A (ja)	2016-09-29
JP6243472B2 (ja)	2017-12-06
US20160058745A1 (en)	2016-03-03
HK1190622A1 (zh)	2014-07-11
AU2011343039B2 (en)	2017-03-02
US20150209368A1 (en)	2015-07-30
US9763947B2 (en)	2017-09-19
EP2651404A2 (en)	2013-10-23
AU2017200812B2 (en)	2019-01-03
ES2650744T3 (es)	2018-01-22
JP2017025080A (ja)	2017-02-02
AU2017200812A1 (en)	2017-03-02

Publication	Publication Date	Title
US20140031547A1 (en)	2014-01-30	CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US11155561B2 (en)	2021-10-26	Substituted glutarimides as Btk inhibitors
KR100823382B1 (ko)	2008-04-17	Ｆａｂｉ 억제제
TWI437989B (zh)	2014-05-21	４－（４－吡啶基）－苯甲醯胺及其作為Ｒｈｏ激酶（ＲＯＣＫ）活性調節劑之用途
US8883819B2 (en)	2014-11-11	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US7338966B2 (en)	2008-03-04	Substituted oxindole derivatives as tyrosine kinase inhibitors
US20050261331A1 (en)	2005-11-24	Substituted pyrrolopyridines
US11472772B2 (en)	2022-10-18	S1P3 antagonists
JP2002501532A (ja)	2002-01-15	新規血管形成阻害薬
TW201536772A (zh)	2015-10-01	磷脂酸肌醇３－激酶抑制劑
US20170037044A1 (en)	2017-02-09	Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
KR19990029570A (ko)	1999-04-26	도파민 작용물질 요법과 관련된 운동 이상증을 치료하기 위한알파-아미노-3-하이드록시-5-메틸-4-이속사졸프로피온산 수용 체길항제를 포함한약학 조성물
US20150119387A1 (en)	2015-04-30	Compound as WNT Signaling Inhibitor, Composition, and Use Thereof
TW201427944A (zh)	2014-07-16	作爲ｐ２ｘ７受體拮抗劑之吲哚羧醯胺衍生物
US20080293785A1 (en)	2008-11-27	Substituted benzothiazole kinase inhibitors
CN112189012B (zh)	2024-02-13	作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
US6730684B1 (en)	2004-05-04	Fab I inhibitors
CN111406054A (zh)	2020-07-10	作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
US20150011557A1 (en)	2015-01-08	Benzyl Piperidine Compounds as Lysophosphatidic Acid (LPA) Receptor Antagonist
CN114341145B (zh)	2024-08-16	化学化合物
US20150336991A1 (en)	2015-11-26	Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
CN114075140A (zh)	2022-02-22	作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途

Legal Events

Date	Code	Title	Description
2013-09-19	AS	Assignment	Owner name: ELECTROPHORETICS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHERIDAN, JOSEPH M;HEAL, JONATHAN R;HAMILTON, WILLIAM D.O.;AND OTHERS;REEL/FRAME:031244/0570 Effective date: 20130902
2016-06-24	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Date

Code

Title

Description

2013-09-19

Assignment

Owner name: ELECTROPHORETICS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHERIDAN, JOSEPH M;HEAL, JONATHAN R;HAMILTON, WILLIAM D.O.;AND OTHERS;REEL/FRAME:031244/0570

Effective date: 20130902

2016-06-24

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION